I-O is 'probably under-hyped,' says Scancell chairman

Existing and potential investors, along with market analysts and other interested parties, crammed into an auditorium at London’s Royal Society of Medicine on Friday for an update on UK-based oncology specialist Scancell (LSE: SCLP).

It is easy to imagine why investors might deem Scancell worth a closer look. At first glance, it ticks a lot of boxes, including having two differentiated innovative platforms, potentially exciting assets in multiple indications that are about to enter the clinic, experienced leadership and partnerships with the world’s leading cancer research charity and Europe’s largest privately-held biotech company

But Scancell’s area of research alone might have been enough to grab the attention of investors, given its current status as pharma’s hottest space.